ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitamin D, Chronic Kidney Disease (CKD) and the Microcirculation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00882401
Recruitment Status : Completed
First Posted : April 16, 2009
Last Update Posted : March 22, 2011
Sponsor:
Information provided by:
Barts & The London NHS Trust

April 15, 2009
April 16, 2009
March 22, 2011
April 2009
October 2010   (Final data collection date for primary outcome measure)
Microcirculatory function - iontophoresis [ Time Frame: 6 months ]
Same as current
Complete list of historical versions of study NCT00882401 on ClinicalTrials.gov Archive Site
Key clinical parameters of CKD management [ Time Frame: 6 months ]
Same as current
Not Provided
Not Provided
 
Vitamin D, Chronic Kidney Disease (CKD) and the Microcirculation
The Effect of Vitamin D on the Microcirculation of Patients With Chronic Kidney Disease (CKD) and Vitamin D Deficiency

Overall research aims: This study will examine the effect of vitamin D supplementation on the function of the endothelium and microcirculation of patients with chronic kidney disease and vitamin D deficiency.

Hypothesis: Vitamin D therapy in patients with CKD and concomitant vitamin D deficiency will improve endothelial, and therefore microcirculatory function, reduce levels of oxidative stress and thus reduce the risk of future CVS events in this population.

Research rationale: Cardiovascular (CVS) diseases are the major cause of death in patients with chronic kidney disease (CKD), accounting for approximately half of all deaths. Patients with CKD are far more likely to die of CVS disease than progress to end stage renal disease. Recently, vitamin D deficiency has been identified as a non-traditional CVS risk factor. However, vitamin D is not routinely prescribed in the early stages of CKD.

Previous publications have established that endothelial, and therefore, microcirculatory dysfunction is a marker of CVS health and a predictor of future CVS events. Studies have also shown that clinical assessments of the microcirculation reflect the overall health and function of the endothelium. Vitamin D has been shown to improve endothelial function in diabetic patients with vitamin D deficiency and normal kidney function. However, no study has examined endothelial dysfunction in patients with CKD and vitamin D deficiency.

With the prevalence of CKD and concomitant vitamin D deficiency increasing worldwide, there is a pressing need to examine the effects of vitamin D therapy in the early stages of CKD. This study involves the use of four, non-invasive, detailed assessments of the microcirculation which could be used in a clinical setting to enhance CVS risk profiling. The current study design includes novel clinical and in vitro work examining endothelial function, oxidative stress levels and potential cellular mechanisms by which vitamin D improves endothelial function. Early detection of endothelial dysfunction, before end stage renal disease is reached, will provide a powerful tool for predicting future CVS events and thus provide an opportunity to intervene with therapies, including vitamin D, at an early stage of renal dysfunction.

Study objectives: Primary study objective - to evaluate the effects of vitamin D therapy on endothelial function in patients with CKD and vitamin D deficiency. Secondary study objective: to evaluate the effects of vitamin D therapy on key clinical parameters in patients with CKD and vitamin D deficiency.

Research plan: We will conduct a double blind, randomised control trial comparing oral ergocalciferol to a placebo in adult, non-diabetic patients with CKD stages 3-4 and vitamin D deficiency (defined as < 10ng/ml (<30nmol/L)). Based on power calculations, 40 subjects will be recruited in each arm as well as 15 healthy control subjects. Subjects will be followed for 7 months in total.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Chronic Kidney Disease
  • Vitamin D Deficiency
  • Drug: Ergocalciferol (Vitamin D)
    ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
    Other Name: Drisdol
  • Drug: Placebo
    Matching placebo at same dose schedule as ergocalciferol
  • Active Comparator: Ergocalciferol (oral)
    ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
    Intervention: Drug: Ergocalciferol (Vitamin D)
  • Placebo Comparator: Placebo
    Matching placebo at same dose schedule as ergocalciferol
    Intervention: Drug: Placebo
Dreyer G, Tucker AT, Harwood SM, Pearse RM, Raftery MJ, Yaqoob MM. Ergocalciferol and microcirculatory function in chronic kidney disease and concomitant vitamin d deficiency: an exploratory, double blind, randomised controlled trial. PLoS One. 2014 Jul 9;9(7):e99461. doi: 10.1371/journal.pone.0099461. eCollection 2014.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
64
Same as current
October 2010
October 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. eGFR between 15 and 60 ml/min/1.73m2
  2. Serum 25 (OH) vitamin D levels <30nmol/L
  3. No evidence of diabetes mellitus (fasting blood sugar <7.1, not taking any diabetic medication)
  4. Not receiving haemo or peritoneal dialysis
  5. No dialysis therapy within the last 3 months
  6. Age > 18 years and < 80 years
  7. Patient agrees not use any medications (prescribed or over-the-counter including herbal remedies) judged to be clinically significant by the Principal Investigator during the course of the study.
  8. Able to understand and sign the written Informed Consent Form.
  9. Able and willing to follow the Protocol requirements.

Exclusion Criteria:

  1. Currently receiving oral ergocalciferol at any dose
  2. Received IM ergocalciferol therapy within last 3 months
  3. Receiving renal replacement therapy of any type or having recently received any form of dialysis (within 3 months)
  4. Pacemaker or any other implanted cardiac device
  5. Serum calcium above 2.6 mmol/L at screening
  6. Pregnant or lactating
  7. Known hypersensitivity to ergocalciferol
  8. Patient known to have a condition which predisposes to hypercalcaemia (multiple myeloma, sarcoidosis, other granulomatous disease)
  9. Initial blood pressure of >160/100 mmHg
  10. History of significant liver disease or cirrhosis
  11. Anticipated requirement for dialysis in 6 months
  12. Malabsorption, severe chronic diarrhea, or ileostomy
  13. Known diagnosis of hypervitaminosis D
  14. Known to have diabetes mellitus
  15. Known to have renal calculi
  16. Known to have systemic sclerosis, Raynaud's phenomenon or other disease associated with known microcirculatory dysfunction
  17. Concurrent participation in any other research study
  18. Unwilling or unable to complete study protocol
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00882401
2008-008745-38
EUDRACT number 2008-008745-38
No
Not Provided
Not Provided
Dr Gavin Dreyer, Barts & The London NHS Trust
Barts & The London NHS Trust
Not Provided
Study Chair: Magdi Yaqoob, MB ChB Barts and the London NHS Trust
Barts & The London NHS Trust
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP